{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:29:09Z","timestamp":1790980149732,"version":"4.1.0"},"reference-count":210,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1301600"],"award-info":[{"award-number":["2021YFA1301600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.mcpro.2023.100578","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:03:53Z","timestamp":1684465433000},"page":"100578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Mass Spectrometry\u2013Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective"],"prefix":"10.1016","volume":"22","author":[{"given":"Liujia","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangzhi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-7651","authenticated-orcid":false,"given":"Tiannan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2023.100578_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2023.100578_bib2","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2023.100578_bib3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mcpro.2023.100578_bib4","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1038\/527S217a","article-title":"Ovarian cancer: beyond resistance","volume":"527","author":"Holmes","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"Oceans: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib11","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih Ie","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mcpro.2023.100578_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib18","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.mcpro.2023.100578_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju297","article-title":"Molecular subtypes of high-grade serous ovarian cancer: the holy grail?","volume":"106","author":"Waldron","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.mcpro.2023.100578_bib21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1158\/0008-5472.CAN-20-2222","article-title":"Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability","volume":"81","author":"Shrestha","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1067\/mob.2003.408","article-title":"Endometriosis and ovarian cancer: thoughts on shared pathophysiology","volume":"189","author":"Ness","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.mcpro.2023.100578_bib23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib25","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-015-0210-y","article-title":"Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors","volume":"7","author":"Ryland","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918768232","article-title":"First-line treatment of ovarian cancer: questions and controversies to address","volume":"10","author":"Ledermann","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib28","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib31","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib32","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","article-title":"CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer","volume":"18","author":"Nielsen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib34","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib35","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","article-title":"Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma","volume":"67","author":"Kryczek","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib40","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib41","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib42","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib43","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A\u00a0phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib45","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined Nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib46","first-page":"183","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2023.100578_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.mcpro.2023.100578_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib51","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","article-title":"Mass spectrometry-based proteomics","volume":"422","author":"Aebersold","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib52","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1016\/j.cell.2021.08.015","article-title":"SnapShot: clinical proteomics","volume":"184","author":"Zhu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113844","article-title":"High-throughput proteomics and AI for cancer biomarker discovery","volume":"176","author":"Xiao","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mcpro.2023.100578_bib54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature19949","article-title":"Mass-spectrometric exploration of proteome structure and function","volume":"537","author":"Aebersold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41592-020-0781-4","article-title":"TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples","volume":"17","author":"Li","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2023.100578_bib56","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1074\/mcp.RA119.001472","article-title":"Multibatch TMT reveals false positives, batch effects and missing values","volume":"18","author":"Brenes","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201900276","article-title":"Data-independent acquisition mass spectrometry-based proteomics and software tools: a glimpse in 2020","volume":"20","author":"Zhang","year":"2020","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13059-018-1547-5","article-title":"SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation","volume":"19","author":"Budnik","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib59","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202110798","article-title":"Ultra-high sensitivity mass spectrometry quantifies single-cell proteome changes upon perturbation","volume":"18","author":"Brunner","year":"2022","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib60","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.molcel.2022.05.022","article-title":"Unbiased spatial proteomics with single-cell resolution in tissues","volume":"82","author":"Mund","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib61","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1038\/s41467-022-34824-2","article-title":"Spatially resolved proteomics via tissue expansion","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100179","article-title":"Scaling up single-cell proteomics","volume":"21","author":"Slavov","year":"2022","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc2831","article-title":"Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer","volume":"10","author":"Kulasingam","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-018-0460-6","article-title":"Mass spectrometry-based proteomics techniques and their application in ovarian cancer research","volume":"11","author":"Swiatly","year":"2018","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trsl.2018.11.001","article-title":"The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers","volume":"206","author":"Carvalho","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib66","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3390\/molecules26092674","article-title":"Quantitative mass spectrometry-based proteomics for biomarker development in ovarian cancer","volume":"26","author":"Ryu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.mcpro.2023.100578_bib67","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14789450.2016.1233065","article-title":"Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy","volume":"13","author":"Deng","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-014-9547-8","article-title":"Proteomics of ovarian cancer: functional insights and clinical applications","volume":"34","author":"Elzek","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.mcpro.2023.100578_bib69","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/mas.21618","article-title":"Mass spectrometry-based mitochondrial proteomics in human ovarian cancers","volume":"39","author":"Li","year":"2020","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.mcpro.2023.100578_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/proteomes9020025","article-title":"Comprehending the proteomic landscape of ovarian cancer: a road to the discovery of disease biomarkers","volume":"9","author":"Mukherjee","year":"2021","journal-title":"Proteomes"},{"key":"10.1016\/j.mcpro.2023.100578_bib71","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3390\/cancers13092067","article-title":"Proteomic studies on the management of high-grade serous ovarian cancer patients: a mini-review","volume":"13","author":"Bradbury","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100578_bib72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14789450.2019.1666004","article-title":"Proteomics advances for precision therapy in ovarian cancer","volume":"16","author":"Labrie","year":"2019","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104001","article-title":"Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis","volume":"79","author":"Xiao","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mcpro.2023.100578_bib74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/proteomes10020016","article-title":"Applications of proteomics in ovarian cancer: dawn of a new era","volume":"10","author":"Ghose","year":"2022","journal-title":"Proteomes"},{"key":"10.1016\/j.mcpro.2023.100578_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijms.2021.116679","article-title":"Toward improvement of screening through mass spectrometry-based proteomics: ovarian cancer as a case study","volume":"469","author":"Luu","year":"2021","journal-title":"Int. J. Mass Spectrom."},{"key":"10.1016\/j.mcpro.2023.100578_bib76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib77","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1021\/pr200603h","article-title":"A\u00a0xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer","volume":"11","author":"Tang","year":"2012","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib78","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/prca.201400063","article-title":"Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies","volume":"8","author":"Timms","year":"2014","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2023.100578_bib79","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/ijc.30020","article-title":"Protein Z: a putative novel biomarker for early detection of ovarian cancer","volume":"138","author":"Russell","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib80","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1074\/mcp.RA118.001221","article-title":"A\u00a0targeted mass spectrometry strategy for developing proteomic biomarkers: a case study of epithelial ovarian cancer","volume":"18","author":"Huttenhain","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/179040","article-title":"Proteomics analysis for finding serum markers of ovarian cancer","volume":"2014","author":"Cheng","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.mcpro.2023.100578_bib82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5301\/JBM.2011.8616","article-title":"Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses","volume":"26","author":"Wang","year":"2011","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.mcpro.2023.100578_bib83","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1078-0432.CCR-05-0461","article-title":"Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine","volume":"12","author":"Ye","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00016340802443830","article-title":"Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology","volume":"88","author":"Petri","year":"2009","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.mcpro.2023.100578_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201700135","article-title":"Discovery and validation of novel protein biomarkers in ovarian cancer patient urine","volume":"12","author":"Sandow","year":"2018","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2023.100578_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.712196","article-title":"A\u00a0novel classifier based on urinary proteomics for distinguishing between benign and malignant ovarian tumors","volume":"9","author":"Ni","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib87","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1074\/mcp.M800313-MCP200","article-title":"Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers","volume":"8","author":"Kuk","year":"2009","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib88","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1074\/mcp.M114.041194","article-title":"Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication","volume":"13","author":"Shender","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib89","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1021\/pr0703223","article-title":"A\u00a0proteome resource of ovarian cancer ascites: Integrated proteomic and bioinformatic analyses to identify putative biomarkers","volume":"7","author":"Gortzak-Uzan","year":"2008","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib90","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1021\/pr1011087","article-title":"In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry","volume":"10","author":"Elschenbroich","year":"2011","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib91","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1021\/acs.jproteome.7b00467","article-title":"The human plasma proteome draft of 2017: building on the human plasma PeptideAtlas from mass spectrometry and complementary assays","volume":"16","author":"Schwenk","year":"2017","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib92","doi-asserted-by":"crossref","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib93","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-020-17033-7","article-title":"Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona","volume":"11","author":"Blume","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2023.100578_bib95","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1126\/science.aaq1327","article-title":"Co-regulatory networks of human serum proteins link genetics to disease","volume":"361","author":"Emilsson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2023.100578_bib96","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: CA125 and beyond","volume":"15 Suppl 3","author":"Bast","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib97","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.mcpro.2023.100578_bib99","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.5858\/2002-126-1518-PATTMD","article-title":"Proteomic approaches to tumor marker discovery - identification of biomarkers for ovarian cancer","volume":"126","author":"Rai","year":"2002","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib100","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib101","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"Coleman","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.mcpro.2023.100578_bib102","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mcpro.2023.100578_bib103","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/dji054","article-title":"Lessons from controversy: ovarian cancer screening and serum proteomics","volume":"97","author":"Ransohoff","year":"2005","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.mcpro.2023.100578_bib104","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14789450.4.1.51","article-title":"Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices","volume":"4","author":"Poon","year":"2007","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib105","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.1073\/pnas.1712731114","article-title":"Selected reaction monitoring approach for validating peptide biomarkers","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib106","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cels.2019.03.011","article-title":"N-glycoproteomics of patient-derived xenografts: a strategy to discover tumor-associated proteins in high-grade serous ovarian cancer","volume":"8","author":"Sinha","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.mcpro.2023.100578_bib107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jprot.2016.05.005","article-title":"A\u00a0proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics","volume":"145","author":"Poersch","year":"2016","journal-title":"J.\u00a0Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/1177271917710948","article-title":"Data-independent acquisition and parallel reaction monitoring mass spectrometry identification of serum biomarkers for ovarian cancer","volume":"12","author":"Rauniyar","year":"2017","journal-title":"Biomark Insights"},{"key":"10.1016\/j.mcpro.2023.100578_bib109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0748-7983(96)80009-6","article-title":"Malignant ascites: a 2-year review from a teaching hospital","volume":"22","author":"Parsons","year":"1996","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib112","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1559-0275-9-14","article-title":"Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers","volume":"9","author":"Kristjansdottir","year":"2012","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1559-0275-10-4","article-title":"Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ","volume":"10","author":"Kristjansdottir","year":"2013","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib114","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cam4.282","article-title":"Early inflammatory response in epithelial ovarian tumor cyst fluids","volume":"3","author":"Kristjansdottir","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2015.07.014","article-title":"Exosomes: emerging biomarkers and targets for ovarian cancer","volume":"367","author":"Tang","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mcpro.2023.100578_bib117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13048-020-0609-y","article-title":"Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells","volume":"13","author":"Cheng","year":"2020","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib118","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1074\/mcp.RA119.001362","article-title":"Microvesicle proteomic profiling of uterine liquid biopsy for ovarian cancer early detection","volume":"18","author":"Barnabas","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib119","first-page":"1719","article-title":"Proteomics profiling of plasma exosomes in epithelial ovarian cancer: a potential role in the coagulation cascade, diagnosis and prognosis","volume":"54","author":"Zhang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib120","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1186\/s12885-019-6176-1","article-title":"Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011137","article-title":"Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer","volume":"5","author":"Amon","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2023.100578_bib122","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cels.2021.06.006","article-title":"Artificial intelligence for proteomics and biomarker discovery","volume":"12","author":"Mann","year":"2021","journal-title":"Cell Syst."},{"key":"10.1016\/j.mcpro.2023.100578_bib123","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated proteogenomic characterization of human high-grade serous ovarian cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib125","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/srep34949","article-title":"Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research","volume":"6","author":"Hughes","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcpro.2023.100578_bib127","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-18-3818","article-title":"Proteomics-derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma","volume":"25","author":"Dieters-Castator","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib128","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2023.100578_bib129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib131","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician's choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib132","doi-asserted-by":"crossref","first-page":"v897","DOI":"10.1093\/annonc\/mdz394.058","article-title":"LBA61-a randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","volume":"30","author":"Gershenson","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib133","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ebiom.2018.12.039","article-title":"Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: reanalysis of CPTAC ovarian cancer","volume":"40","author":"Tong","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mcpro.2023.100578_bib134","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/s41467-020-19976-3","article-title":"Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer","volume":"11","author":"Pan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/path.6006","article-title":"The proteome of clear cell ovarian carcinoma","volume":"258","author":"Ji","year":"2022","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib136","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1210\/en.2014-1977","article-title":"The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice","volume":"156","author":"Kim","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.mcpro.2023.100578_bib137","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A\u00a0candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib138","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib139","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib141","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib143","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.celrep.2017.03.015","article-title":"Phosphoproteomics of primary cells reveals druggable kinase signatures in ovarian cancer","volume":"18","author":"Francavilla","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2023.100578_bib144","article-title":"Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability","volume":"1","author":"McDermott","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","article-title":"ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer","volume":"49","author":"Matulonis","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib146","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","article-title":"A\u00a0clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the princess margaret phase II consortium","volume":"24","author":"Lheureux","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib147","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib148","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with Nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib150","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib151","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mcpro.2023.100578_bib152","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/1878-0261.12883","article-title":"HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer","volume":"15","author":"Lombardi","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib153","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2011.10.002","article-title":"A\u00a0phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma","volume":"124","author":"Hendrickson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib154","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cell.2018.08.065","article-title":"Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer","volume":"175","author":"Coscia","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib156","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib157","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/2326-6066.CIR-13-0089","article-title":"Effect of montanide and poly-ICLC adjuvant on human self\/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial","volume":"1","author":"Tsuji","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib158","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100578_bib159","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib161","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib162","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","article-title":"Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts","volume":"569","author":"Eckert","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100578_bib163","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","article-title":"Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer","volume":"28","author":"Makhija","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib164","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/ijgc-2019-000370","article-title":"Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer","volume":"29","author":"Lorusso","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib165","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","article-title":"Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE)","volume":"34","author":"Kurzeder","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib166","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.mcpro.2023.100578_bib167","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib168","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barabasi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mcpro.2023.100578_bib169","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1746-1596-8-190","article-title":"Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.mcpro.2023.100578_bib170","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1158\/1541-7786.MCR-10-0398","article-title":"Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells","volume":"8","author":"Li","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib171","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1026596609969","article-title":"Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors","volume":"18","author":"Hu","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.mcpro.2023.100578_bib172","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.7150\/jca.20639","article-title":"Inhibition of transient receptor potential vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model","volume":"9","author":"Xue","year":"2018","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib173","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2010.05.032","article-title":"Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer","volume":"118","author":"Staff","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib174","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2147\/OTT.S138833","article-title":"SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Hu","year":"2017","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.mcpro.2023.100578_bib175","first-page":"4914","article-title":"NOTCH2\/NOTCH3\/DLL3\/MAML1\/ADAM17 signaling network is associated with ovarian cancer","volume":"17","author":"Jia","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcpro.2023.100578_bib176","first-page":"3567","article-title":"Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib177","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib178","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41587-021-00860-4","article-title":"Ultra-fast proteomics with scanning SWATH","volume":"39","author":"Messner","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2023.100578_bib179","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41421-022-00441-y","article-title":"Enhanced inflammation and suppressed adaptive immunity in COVID-19 with prolonged RNA shedding","volume":"8","author":"Tang","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.mcpro.2023.100578_bib180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41421-022-00418-x","article-title":"Proteomic characterization of omicron SARS-CoV-2 host response","volume":"8","author":"Bao","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.mcpro.2023.100578_bib181","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/pmic.201300187","article-title":"Beyond antibodies: new affinity reagents to unlock the proteome","volume":"14","author":"Lollo","year":"2014","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib182","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.7150\/thno.37549","article-title":"Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment","volume":"9","author":"Finkernagel","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.mcpro.2023.100578_bib183","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s42003-019-0464-9","article-title":"High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer","volume":"2","author":"Enroth","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.mcpro.2023.100578_bib184","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fonc.2019.01150","article-title":"Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma","volume":"9","author":"Graumann","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib185","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41416-021-01697-z","article-title":"Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer","volume":"126","author":"Mukama","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2023.100578_bib186","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s43856-022-00193-6","article-title":"Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment","volume":"2","author":"Enroth","year":"2022","journal-title":"Commun. Med. (Lond)"},{"key":"10.1016\/j.mcpro.2023.100578_bib187","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ygyno.2018.12.015","article-title":"A\u00a0combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer","volume":"152","author":"Mysona","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110271","article-title":"Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19","volume":"38","author":"Bi","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2023.100578_bib189","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1074\/mcp.R800001-MCP200","article-title":"Urine in clinical proteomics","volume":"7","author":"Decramer","year":"2008","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41467-017-00249-5","article-title":"Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry","volume":"8","author":"Collins","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib191","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100578_bib192","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.aan6828","article-title":"Single-cell transcriptomics to explore the immune system in health and disease","volume":"358","author":"Stubbington","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2023.100578_bib193","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41576-021-00370-8","article-title":"Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics","volume":"22","author":"Longo","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mcpro.2023.100578_bib194","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41587-022-01302-5","article-title":"Deep visual proteomics defines single-cell identity and heterogeneity","volume":"40","author":"Mund","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2023.100578_bib195","doi-asserted-by":"crossref","first-page":"12195","DOI":"10.1021\/acs.analchem.0c05372","article-title":"Toward high spatially resolved proteomics using expansion microscopy","volume":"93","author":"Drelich","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.mcpro.2023.100578_bib196","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1038\/s41467-022-35367-2","article-title":"In-depth mapping of protein localizations in whole tissue by micro-scaffold assisted spatial proteomics (MASP)","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100578_bib197","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A\u00a0single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100578_bib198","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the dependency of cellular protein levels on mRNA abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2023.100578_bib199","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","article-title":"Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry","volume":"22","author":"Gonzalez","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2023.100578_bib200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41592-023-01771-9","article-title":"Making single-cell proteomics biologically relevant","volume":"20","author":"Rosenberger","year":"2023","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2023.100578_bib201","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jcb.22413","article-title":"Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line","volume":"109","author":"Li","year":"2010","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.mcpro.2023.100578_bib202","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/pr060402r","article-title":"Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines","volume":"6","author":"Yan","year":"2007","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib203","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1021\/pr300403d","article-title":"Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer","volume":"11","author":"Chappell","year":"2012","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib204","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1002\/pmic.200900685","article-title":"Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines","volume":"10","author":"Dai","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2023.100578_bib205","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.7150\/thno.8502","article-title":"Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer","volume":"4","author":"Chen","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.mcpro.2023.100578_bib206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/15548627.2014.998931","article-title":"TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer","volume":"11","author":"Zhang","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.mcpro.2023.100578_bib207","first-page":"9793","article-title":"Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcpro.2023.100578_bib208","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/0008-5472.CAN-09-3215","article-title":"Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer","volume":"70","author":"Yan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib209","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1021\/pr100478u","article-title":"Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells","volume":"9","author":"Lee","year":"2010","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2023.100578_bib210","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/cas.12710","article-title":"Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines","volume":"106","author":"Chen","year":"2015","journal-title":"Cancer Sci."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947623000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947623000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:12:30Z","timestamp":1761527550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947623000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":210,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1535947623000890"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2023.100578","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mass Spectrometry\u2013Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2023.100578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100578"}}